Citicoline - OPKO

Drug Profile

Citicoline - OPKO

Alternative Names: Citoneurox; Cytidine diphosphate choline

Latest Information Update: 23 Feb 2016

Price : $50

At a glance

  • Originator OPKO Health
  • Class Neuroprotectants; Nootropics; Pyrimidine nucleotides; Small molecules; Trimethyl ammonium compounds
  • Mechanism of Action Hydroxy radical formation inhibitors; Phosphatidylcholine stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Neurological disorders; Stroke

Most Recent Events

  • 21 Oct 2013 OPKO receives final marketing approval from Agencia Espanola de Medicamentos y Productos Sanitarios for citicoline in Spain
  • 24 Jul 2013 Registered for Neurological disorders in Spain (PO)
  • 24 Jul 2013 Registered for Neurological disorders in Spain (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top